LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
April 21, 2023 08:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other...
LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 27, 2023 08:36 ET
|
LianBio
Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing, with data expected mid-year 2023 Phase 3 registrational trial of TP-03 in...
Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore
December 19, 2022 07:00 ET
|
LianBio; Pfizer Inc.
Pfizer will now lead all development and commercialization activities in Mainland China, Hong Kong, Macau, and Singapore LianBio will receive a $20 million upfront payment, to be released from...
LianBio Announces President and Chief Strategy Officer Departure
December 13, 2022 17:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
November 01, 2022 16:05 ET
|
LianBio
• LIBRA trial designed to support registration in China• Topline results expected in the fourth quarter of 2023 SHANGHAI and PRINCETON, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq:...
LianBio to Participate in June Investor Events
June 02, 2022 16:02 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers
May 09, 2022 08:00 ET
|
LianBio
Mavacamten demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers Study was conducted in parallel with ongoing Phase 3 EXPLORER-CN trial of mavacamten...
LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial Results
December 09, 2021 16:30 ET
|
LianBio
Initiated and completed dosing in pharmacokinetic (PK) study of mavacamten in healthy Chinese volunteers Initiated Phase 2a clinical trial of infigratinib in Chinese patients with gastric cancer and...
LianBio Announces Pricing of Initial Public Offering
October 31, 2021 20:21 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., Oct. 31, 2021 (GLOBE NEWSWIRE) -- LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets,...